News und Analysen
Quantum Genomics announces the end of its collaboration with Chinese Pharma Qilu in the development and commercialization of firibastat in China
Quantum Genomics announces the end of its collaboration with Chinese Pharma Qilu in the development and commercialization of firibastat in China
Quantum Genomics (Euronext Growth - FR0011648971 -
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Valbiotis startet Kapitalerhöhung durch Privatplatzierung
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis: Weitgehend erfolgreiche Kapitalerhöhung durch Privatplatzierung in Höhe von 15 Millionen Euro
Regulatorische Nachrichten:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of
Valbiotis Launches a Capital Increase Through a Private Placement
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today
Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/
Figure 1: Effect of TOTUM•854 supplementation on
Valbiotis stellt positive präklinische Ergebnisse von TOTUM•854 bei der Prävention von Bluthochdruck auf der gemeinsamen Jahrestagung der ESH-ISH vor
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary
THERANEXUS : 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS
Lyon, 7 April 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Sensorion Senior Management to Attend Four Conferences in April 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Quantum Genomics Reports Full Year 2020 Operating and Financial Results
Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients
Finalization of recruitment for Phase IIb trial in heart failure with upcoming
Sensorion Publishes Results of Extraordinary General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS erhält die ISO 9001-Zertifizierung für seine Aktivitäten im Bereich „Design, Entwicklung und Produktionskontrolle von Lösungen zur Vorbeugung und Bekämpfung von Stoffwechsel- und Herz-Kreislauf-Erkrankungen“
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL/PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
VALBIOTIS Obtains ISO 9001 Certification for Its Activities in "Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases"
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a French Research & Development company committed to scientific innovation for preventing and combating
VALBIOTIS veröffentlicht seine Jahresbilanz 2020
Pflichtmitteilung:
Highlights und Ergebnisse 2020
-
Globale strategische Partnerschaft mit Nestlé Health Science zur Entwicklung und Vermarktung von TOTUM-63, einem pflanzlichen Wirkstoff mit
Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’), a late-stage clinical biotechnology company pioneering physics-based approaches to
VALBIOTIS Releases Its 2020 Annual Results
Regulatory News:
2020 highlights and results
-
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with
Sensorion to Present at Two Conferences on March 16th 2021
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and